Researchers developed a deep learning-driven MASLD classification system for precision risk management.
Key Details
- 1Study analyzed 1,111 liver biopsies to train a deep LASSO model using six clinical indicators.
- 2Algorithm defined four MASLD subtypes with distinct risk profiles for hepatic and extrahepatic complications.
- 3External validation performed in cohorts of 6,172 and 7,406 adults; clustering was consistent.
- 4Cluster 4 displayed highest risk for combined cardiovascular, liver, and kidney complications, and high frequency of PNPLA3 risk alleles.
- 5The classification intends to tailor interventions, such as prioritizing fibrosis screening or cardiorenal protection, by subtype.
Why It Matters
The use of advanced AI/machine learning in clinical stratification sets a precedent for data-driven, precision approaches in metabolic and cardiometabolic disease management. Implications exist for integration with imaging biomarkers and improving targeted clinical decision-making in radiology and hepatology.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.